Corline Biomedical AB (CLBIO) — Capital Reinvestment Ratio
Corline Biomedical AB (CLBIO) has a Capital Reinvestment Ratio of 0.80x as of March 2024, meaning it reinvests 1% of its operating cash flow (Skr2.30 Million) in capital expenditures (Skr1.83 Million). Check how tangible is Corline Biomedical AB's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Corline Biomedical AB Capital Reinvestment Ratio (2023–2023)
This chart tracks Corline Biomedical AB's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see CLBIO cash flow conversion.
Annual Capital Reinvestment Ratio for Corline Biomedical AB (2023–2023)
Year-by-year Capital Reinvestment Ratio for Corline Biomedical AB from 2023 to 2023. See CLBIO cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 11.99x | Skr886.00K | Skr10.62 Million | — |